Анализ синдрома поликистозных яичников с точки зрения риска развития сердечно-сосудистых заболеваний
Аннотация
Цель обзора. Дать определение и рассмотреть основные патогенетические механизмы синдрома поликистозных яичников (СПКЯ) и его связь с кардиометаболическими факторами риска.
Материалы и методы. Материал для обзорной статьи был собран из рецензируемых статей, опубликованных в PubMed, eLIBRARY.RU, КиберЛенинка и других исследовательских платформах с 2006 года по 2024 годы.
Результаты. При различных вариантах СПКЯ отслеживаются некоторые особенности риска сердечно-сосудистых заболеваний (ССЗ). Скрининг риска ССЗ остается критически важным в этой популяции пациенток, поскольку улучшения метаболического профиля и снижения риска ССЗ можно достичь при сочетании ведения образа жизни и фармакотерапии.
Заключение. Необходимы дополнительные исследования, чтобы определить наиболее эффективные способы снижения риска ССЗ, связанных с СПКЯ.
Об авторах
Елизавета СавчукРоссия
Отделение вторичной профилактики хронических неинфекционных заболеваний
Inna Druk
Россия
Mekhman Mamedov
Россия
Отделение вторичной профилактики хронических неинфекционных заболеваний
Список литературы
1. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Health Res 2018;15:2589. DOI: 10.3390/ijerph15112589.
2. Witchel SF, Oberfield ShE, Peña AS Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endo Soc. 2019;3(8):1545-1573. DOI: 10.1210/js.2019-00078.
3. Yasmin A, Roychoudhury S, Paul Choudhury A et al. Polycystic Ovary Syndrome: An Updated Overview Foregrounding Impacts of Ethnicities and Geographic Variations. Life (Basel). 2022 Nov 25;12(12):1974. DOI: 10.3390/life12121974.
4. Rodriguez-Paris D, Remlinger-Molenda A, Kurzawa R et al. Psychiatric disorders in women with polycystic ovary syndrome. Psychiatr Pol. 2019 Aug 31;53(4):955-966. DOI: 10.12740/PP/OnlineFirst/93105.
5. Dokras A, Stener-Victorin E, Yildiz BO et al. Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Fertil Steril. 2018 May;109(5):888-899. DOI: 10.1016/j.fertnstert.2018.01.038.
6. Li Z, Wang YH, Wang LL et al. Polycystic ovary syndrome and the risk of endometrial, ovarian and breast cancer: An updated meta-analysis. Scott Med J. 2022 Aug;67(3):109-120. DOI: 10.1177/00369330221107099.
7. Aversa A, La Vignera S, Rago R et al. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Front Endocrinol (Lausanne). 2020 Aug 11;11:516. doi: 10.3389/fendo.2020.00516.
8. Kakoly NS, Khomami MB, Joham AE et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Human Reproduction Update. 2018. 24(4): 455–467. DOI: 10.1093/humupd/dmy007.
9. Amiri M, Ramezani Tehrani F et al. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol. 2020 Mar 17;18(1):23. DOI: 10.1186/s12958-020-00576-1.
10. Mimouni NEH, Paiva I, Barbotin AL et al. Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process. Cell Metab. 2021 Mar 2;33(3):513-530.e8. DOI: 10.1016/j.cmet.2021.01.004.
11. Risal S, Pei Y, Lu H et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. Nat Med. 2019 Dec;25(12):1894-1904. DOI: 10.1038/s41591-019-0666-1.
12. Aversa A, La Vignera S, Rago R et al. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Front Endocrinol (Lausanne). 2020 Aug 11;11:516. DOI: 10.3389/fendo.2020.00516.
13. di Clemente N, Racine C, Rey RA. Anti-Müllerian Hormone and Polycystic Ovary Syndrome in Women and Its Male Equivalent. Biomedicines. 2022 Oct 7;10(10):2506. DOI: 10.3390/biomedicines10102506.
14. Aversa A, La Vignera S, Rago R et al. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Front Endocrinol (Lausanne). 2020 Aug 11;11:516. DOI: 10.3389/fendo.2020.00516.
15. Welt CK. Genetics of Polycystic Ovary Syndrome: What is New? Endocrinol Metab Clin North Am. 2021 Mar;50(1):71-82. DOI: 10.1016/j.ecl.2020.10.006.
16. Day F, Karaderi T, Jones MR et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018 Dec 19;14(12):e1007813. DOI: 10.1371/journal.pgen.1007813.
17. van Baal L, Tan S. Das polyzystische Ovarsyndrom als genderspezifischer kardiometabolischer Risikofaktor [Polycystic ovary syndrome as a gender-specific cardiometabolic risk factor]. Inn Med (Heidelb). 2023 Jul;64(7):642-648. German. DOI: 10.1007/s00108-023-01529-7.
18. Wan Z, Zhao J, Ye Y et al. Risk and incidence of cardiovascular disease associated with polycystic ovary syndrome. Eur J Prev Cardiol. 2024 Sep 20;31(13):1560-1570. DOI: 10.1093/eurjpc/zwae066.
19. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Apr;91(4):1357-63. DOI: 10.1210/jc.2005-2430.
20. Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health. 2020 Mar 18;14:2633494120911038. DOI: 10.1177/2633494120911038.
21. Wekker V, van Dammen L, Koning A et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020 Nov 1;26(6):942-960. DOI: 10.1093/humupd/dmaa029.
22. Zhuang C, Luo X, Wang W et al. Cardiovascular Risk According to Body Mass Index in Women of Reproductive Age With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022 Feb 16;9:822079. DOI: 10.3389/fcvm.2022.822079.
23. Ramezani TF, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020 Jan;36(1):12-23. DOI: 10.1080/09513590.2019.1650337.
24. Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol. 2020 Mar 17;18(1):23. DOI: 10.1186/s12958-020-00576-1.
25. Yang F, Wang Z, Sørensen HT, Janszky I, Gissler M, Yuan W, Miao M, Roos N, Wikström AK, Li J, László KD. Maternal polycystic ovary syndrome and Offspring's Risk of Cardiovascular diseases in Childhood and Young Adulthood. Nat Commun. 2024 Nov 29;15(1):10414. DOI: 10.1038/s41467-024-54795-w.
26. Shawky NM. Cardiovascular disease risk in offspring of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2022 Nov 30;13:977819. DOI: 10.3389/fendo.2022.977819.
27. Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health. 2020 Mar 18;14:2633494120911038. DOI: 10.1177/2633494120911038.
28. Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health. 2020 Mar 18;14:2633494120911038. DOI: 10.1177/2633494120911038.
29. Carmina E, Lobo RA. Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome? J Womens Health (Larchmt). 2018 Nov;27(11):1385-1388. DOI: 10.1089/jwh.2018.7162.
30. Azziz R. Does the risk of diabetes and heart disease in women with polycystic ovary syndrome lessen with age? Fertil Steril. 2017 Dec;108(6):959-960. DOI: 10.1016/j.fertnstert.2017.09.034.
31. Çelik Ö, Köse MF. An overview of polycystic ovary syndrome in aging women. J Turk Ger Gynecol Assoc. 2021 Dec 6;22(4):326-333. DOI: 10.4274/jtgga.galenos.2021.2021.0077.
32. Teede HJ, Misso ML, Costello MF et al.; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602-1618. DOI: 10.1093/humrep/dey256.
33. Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R et al. The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018 Feb;88(2):169-184. DOI: 10.1111/cen.13477.
34. Meun C, Franco OH, Dhana K et al. High Androgens in Postmenopausal Women and the Risk for Atherosclerosis and Cardiovascular Disease: The Rotterdam Study. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1622-1630. DOI: 10.1210/jc.2017-02421.
35. Meun C, Gunning MN, Louwers YV et al.; CREW consortium. The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2020 Feb;92(2):150-158. DOI: 10.1111/cen.14117.
36. Helvaci N, Yildiz BO. Cardiovascular health and menopause in aging women with polycystic ovary syndrome. Expert Rev Endocrinol Metab. 2020 Jan;15(1):29-39. DOI: 10.1080/17446651.2020.1719067.
37. Teede HJ, Misso ML, Costello MF et al.; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-379. DOI: 10.1016/j.fertnstert.2018.05.004.
38. Адамян Л.В., Андреева Е.Н., Абсатарова Ю.С. и др. Клинические рекомендации “Синдром поликистозных яичников”. Проблемы Эндокринологии. 2022;68(2):112-127. DOI: 10.14341/probl12874.
39. Lo ACQ, Lo CCW, Oliver-Williams C. Cardiovascular disease risk in women with hyperandrogenism, oligomenorrhea/menstrual irregularity or polycystic ovaries (components of polycystic ovary syndrome): a systematic review and meta-analysis. Eur Heart J Open. 2023 Jun 9;3(4):oead061. DOI: 10.1093/ehjopen/oead061.
40. Aversa A, La Vignera S, Rago R et al. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Front Endocrinol (Lausanne). 2020 Aug 11;11:516. DOI: 10.3389/fendo.2020.00516.
41. Goyal M, Dawood AS. Debates Regarding Lean Patients with Polycystic Ovary Syndrome: A Narrative Review. J Hum Reprod Sci. 2017 Jul-Sep;10(3):154-161. DOI: 10.4103/jhrs.JHRS_77_17.
42. Burns K, Mullin BH, Moolhuijsen LME et al. Body mass index stratified meta-analysis of genome-wide association studies of polycystic ovary syndrome in women of European ancestry. BMC Genomics. 2024 Feb 26;25(1):208. DOI: 10.1186/s12864-024-09990-w.
43. Stuckey BG, Opie N, Cussons AJ et al.Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis. Metabolism. 2014 Aug;63(8):1071-7. DOI: 10.1016/j.metabol.2014.05.004.
44. Zhu T, Cui J, Goodarzi MO. Polycystic Ovary Syndrome and Risk of Type 2 Diabetes, Coronary Heart Disease, and Stroke. Diabetes. 2021 Feb;70(2):627-637. DOI: 10.2337/db20-0800.
45. Zhu T, Goodarzi MO. Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization. J Clin Endocrinol Metab. 2022 Feb 17;107(3):e899-e911. DOI: 10.1210/clinem/dgab757.
46. Zhang X, Huangfu Z, Wang S. No association effect of genetic polymorphism was observed between polycystic ovary syndrome and cardiovascular diseases risk: a mendelian randomization study. Endocrine. 2023 Dec;82(3):695-706. DOI: 10.1007/s12020-023-03467-8.
47. Teede HJ, Misso ML, Costello MF, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-379. DOI: 10.1016/j.fertnstert.2018.05.004.
48. Guan C, Zahid S, Minhas AS et al.Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease. Fertil Steril. 2022 May;117(5):924-935. DOI: 10.1016/j.fertnstert.2022.03.009.
49. Teede HJ, Misso ML, Costello MF et al.; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-379. DOI: 10.1016/j.fertnstert.2018.05.004.
50. Profili NI, Castelli R, Gidaro A et al. Possible Effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): An Update. J Clin Med. 2024 Jan 25;13(3):698. DOI: 10.3390/jcm13030698.
51. Myerson ML, Paparodis RD, Block RC et al. Polycystic ovary syndrome: A review of diagnosis and management, with special focus on atherosclerotic cardiovascular disease prevention. J Clin Lipidol. 2024 Jul-Aug;18(4):e488-e500. DOI: 10.1016/j.jacl.2024.04.131.
52. Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020 Oct;30(7):399-404. DOI: 10.1016/j.tcm.2019.08.010.
Рецензия
Для цитирования:
Савчук Е., Druk I., Mamedov M. Анализ синдрома поликистозных яичников с точки зрения риска развития сердечно-сосудистых заболеваний. Рациональная Фармакотерапия в Кардиологии.
Послать статью по эл. почте 